Blowing the Whistle on One of the Deadliest Prescription Drugs Ever
“Blood Feud rivals A Civil Action for best non-fiction book of the past twenty years.” — John Lescroart, New York Times bestselling author of Damage
Procrit seemed like a biotech miracle, promising a golden age in medical care. Developed in the 1980s by Amgen and licensed to the pharmaceutical giant, Johnson & Johnson, the drug (AKA Epogen and Aranesp) soon generated billions in annual revenue—and still does. In 2012, world famous cyclist, Olympian, and Tour de France champion Lance Armstrong was banned from professional cycling on doping charges for using EPO (the blanket name for the drugs Procrit and Epogen), resulting in a global controversy about abuse, big pharmaceutical companies, and the lies and inaccuracies concerning performance-enhancing drugs.
Mark Duxbury was a J&J salesman who once believed in the blood-booster, setting record sales and winning company awards. Then Duxbury started to learn unsavory truths about Procrit and J&J’s business practices. He was fired and filed a whistleblower suit to warn the public.
When Jan Schlichtman (A Civil Action) learned of Duxbury’s crusade, he signed on. Now, he’s fighting on behalf of cancer patients and for every American who trusts Big Pharma with his life.
Ratings and Reviews
Be the first to review this book!
You've already shared your review for this item. Thanks!
We are currently reviewing your submission. Thanks!
by Kathleen Sharp
Share your thoughts
Tell readers what you thought by rating and reviewing this book.
Rate it *
Please make sure to choose a rating
Add a review* Required
How to write a great review
- Say what you liked best and least
- Describe the author's style
- Explain the rating you gave
- Use rude and profane language
- Include any personal information
- Mention spoilers or the book's price
- Recap the plot
(0) 50 characters minimum
The review must be at least 50 characters long.
The title should be at least 4 characters long.
Display Name *
Your display name should be at least 2 characters long.
Report a review
Would you like us to take another look at this review?
You've successfully reported this review. We appreciate your feedback.
by Kathleen Sharp
Thanks for Sharing!
by on September 29, 2016
- Penguin Publishing Group, August 2012
- Download options:
- EPUB 2 (Adobe DRM)
You can read this item using any of the following Kobo apps and devices: